<DOC>
	<DOCNO>NCT02687984</DOCNO>
	<brief_summary>Primary Objective : To assess relative bioavailability RBP-7000 formulate 2 different molecular weight ( MW ) ( low high MW test treatment ) poly ( DL-lactide-co-glycolide ) carboxylic acid end group ( PLGH ) polymer compare intermediate MW PLGH polymer follow single subcutaneous ( SC ) injection RBP-7000 subject stable schizophrenia . Secondary Objective : To evaluate safety tolerability single SC injection RBP-7000 use PLGH polymer 2 different MW ( low high MW test treatment ) compare intermediate MW polymer subject stable schizophrenia .</brief_summary>
	<brief_title>PK , Safety , Tolerability Study RBP-7000 Different Molecular Weight Polymer Subjects With Schizophrenia</brief_title>
	<detailed_description>This multicenter , randomize , open-label , single-dose , parallel-group study subject clinically stable schizophrenia currently take risperidone . A total approximately 48 subject ( 16 per group ) randomize receive single subcutaneous ( SC ) injection RBP-7000 120 mg formulate PLGH polymer either 21 kilodaltons ( kDa ) ( low MW group ) , 29 kDa PLGH polymer ( high MW group ) , 26 kDa PLGH polymer ( intermediate MW group ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis schizophrenia define DSM5 criterion . Clinically stable schizophrenia , evidence investigator evaluation , outpatient status least 30 day prior screen , confirmation stability caregiver regular supportive contact subject . Otherwise healthy basis physical examination . Body mass index ( BMI ) 18 35 kg/m^2 weight least 49.9 kg screening . Subjects take oral risperidone product ( except test dose 0.25 mg risperidone ) ; subject take risperidone 9hydroxyrisperidone sustainedrelease depot formulation within 120 day prior study screen ; subject receive 3month depot formulation 9hydroxyrisperidone within 2 year study screen . Subjects take clinically relevant inducer inhibitor cytochrome P450 ( CYP ) 2D6 , CYP3A4 , undergone proper washout ( minimum 5 halflives medication ) prohibit medication prior Day 1 . Medications , opinion Investigator conjunction medical monitor , may expect significantly interfere metabolism excretion risperidone and/or 9hydroxyrisperidone ; may associate significant drug interaction risperidone ; may pose significant risk subject 's participation study . Any natural product herbal preparation include vitamin supplement throughout study . Subjects history cancer unless diseasefree ≥5 year ( exception resect basal cell squamous cell carcinoma skin ) . Subjects active medical condition/disorder/disease may either compromise subject safety interfere safety and/or outcome evaluation study drug . Subjects exacerbation schizophrenia last 30 day . Subjects evidence history ( past 6 month prior screen ) significant hepatic disorder may either compromise subject safety interfere safety and/or outcome evaluation study drug , include : Acute chronic hepatitis , include limited hepatitis B C. Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2x ULN . Subjects history severe renal disease , creatinine clearance &lt; 60 mL/min Subjects evidence history orthostatic hypotension within 6 month screen . Subjects absolute neutrophil count &lt; 1.5x 10^9/L ( African African/American &lt; 1.2x 10^9/L ) . Subjects history druginduced leucopenia . Subjects acquire immune deficiency syndrome ( AIDS ) human immunodeficiency virus ( HIV ) positive . Subjects medical condition include , limited , history heart attack ( myocardial infarction ) brain injury ( traumatic injury loss consciousness and/or cerebrovascular accident ) , clinically significant low blood pressure arrhythmia interpret Principal Investigator medically qualify subinvestigator . Subjects congenital long QT syndrome , history prolong QT 3 month prior screen , correct QT interval ( Fridericia QTcF ) &gt; 450 msec ( male ) &gt; 470 msec ( female ) screening ( Visit 1 ) . Subjects suicidal ideation intent plan Subjects uncontrolled depression , opinion Investigator . Subjects diagnosis insulindependent diabetes , hemoglobin A1c ( HbA1c ) ≥8.0 % screening , change diabetic medication regimen 28 day prior sign inform consent document . Subjects prior allergic reaction , sensitivity know contraindication component RBP7000 ( e.g. , risperidone , PLGH NMP ) . Women childbearing potential pregnant breastfeeding , seek pregnancy , fail use adequate contraceptive method study . Subjects presence opioids , cocaine , amphetamine , methadone , barbiturate , benzodiazepine , methamphetamine , cannabinoids , phencyclidine urine assess urine drug screen . Subjects epilepsy seizure disorder , Parkinson 's disease dementia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Long-acting Risperidone</keyword>
	<keyword>Atrigel</keyword>
</DOC>